Pfizer has seen its Nyvepria (pegfilgrastim) biosimilar receive a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending granting a pan-European marketing authorization for the rival to Neulasta.
Typically, the European Commission acts to convert CHMP recommendations into formal approvals within 67 days.






